Phase II Trial of Combined Modality Therapy With Growth Factor Support in Locally Advanced NSCLC

NCT00682383 Phase 2 COMPLETED

To determine the safety and efficacy of administering filgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgrastim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients.

Details

Lead sponsor	Mt. Sinai Medical Center, Miami
Phase	Phase 2
Status	COMPLETED
Enrolment	26
Start date	2003-09
Completion	2010-01

Conditions

• Unresectable Locally Advanced NSCLC

Interventions

• Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta

Primary outcomes

• To determine the safety and efficacy of administering pegfilgrastim with concurrent chemoradiotherapy and the potential benefit of administering pegfilgramstim with consolidation chemotherapy in patients with unresectable locally advanced NSCLC patients. — One year

Countries

United States